iTeos to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 12, 2021
August 05 2021 - 7:00AM
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of highly differentiated immuno-oncology
therapeutics for patients, today announced that it will host a
conference call and live webcast at 8:00 a.m. ET on Thursday,
August 12, 2021 to report its second quarter 2021 financial results
and provide a corporate update.
To pre-register for the call, please use the following link, and
you will receive access details via email.
Webcast
This registration link, along with a live audio webcast, will be
accessible from the Events page of the Company’s IR website at
https://investors.iteostherapeutics.com/news-and-events/events. A
replay will be available on the Company’s website approximately two
hours after completion of the event and for 30 days following the
call
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company
pioneering the discovery and development of a new generation of
highly differentiated immuno-oncology therapeutics for patients.
The Company’s innovative pipeline includes two clinical-stage
programs targeting novel, validated immuno-oncology. The initial
antibody product candidate, EOS-448, is a high affinity, potent,
anti-TIGIT antibody with a functional Fc domain, designed to
enhance the anti-tumor response through a multifaceted immune
modulatory mechanism. An open-label Phase 1 clinical trial of
EOS-448 is ongoing in adult cancer patients with advanced solid
tumors with preliminary data indicating preliminary clinical
activity as a monotherapy and a favorable tolerability profile. The
Company is also advancing inupadenant, a first insurmountable
adenosine A2A receptor antagonist in clinical development tailored
to overcome cancer immunosuppression. iTeos is conducting an
open-label multi-arm Phase 1/2a clinical trial of inupadenant in
adult cancer patients with advanced solid tumors. Preliminary
results indicate encouraging single-agent activity as well as the
identification of a potential predictive biomarker. iTeos
Therapeutics is headquartered in Cambridge, MA with a research
center in Gosselies, Belgium.
For further information, please contact:
Investor Contact:
Ryan Baker iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com
Media Contacts:media@iteostherapeutics.com
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Sep 2023 to Sep 2024